0	10	Inhibition	Inhibition	NNP
11	13	of	of	IN
14	19	human	human	JJ
20	36	immunodeficiency	immunodeficiency	NN
37	42	virus	virus	NN
43	47	type	type	NN
48	49	1	1	CD
50	61	replication	replication	NN
62	64	by	by	IN
65	66	a	a	DT
67	80	Tat-activated	tat-activated	JJ
80	81	,	,	,
82	92	transduced	transduce	VBN
93	103	interferon	interferon	NN
104	108	gene	gene	NN
108	109	:	:	:
110	118	targeted	target	VBN
119	129	expression	expression	NN
130	132	to	to	TO
133	138	human	human	JJ
139	155	immunodeficiency	immunodeficiency	NN
156	161	virus	virus	NN
162	166	type	type	NN
167	177	1-infected	1-infected	JJ
178	183	cells	cell	NNS
183	184	.	.	.

186	188	We	we	PRP
189	193	have	have	VBP
194	202	examined	examine	VBN
203	206	the	the	DT
207	218	feasibility	feasibility	NN
219	221	of	of	IN
222	227	using	use	VBG
228	238	interferon	interferon	NN
239	240	(	(	(
240	243	IFN	IFN	NNP
243	244	)	)	)
245	249	gene	gene	NN
250	258	transfer	transfer	NN
259	261	as	as	IN
262	263	a	a	DT
264	269	novel	novel	JJ
270	278	approach	approach	NN
279	281	to	to	TO
282	292	anti-human	anti-human	JJ
293	309	immunodeficiency	immunodeficiency	NN
310	315	virus	virus	NN
316	320	type	type	NN
321	322	1	1	CD
323	324	(	(	(
324	329	HIV-1	HIV-1	NNP
329	330	)	)	)
331	338	therapy	therapy	NN
339	341	in	in	IN
342	346	this	this	DT
347	352	study	study	NN
352	353	.	.	.

354	356	To	to	TO
357	362	limit	limit	VB
363	373	expression	expression	NN
374	376	of	of	IN
377	378	a	a	DT
379	389	transduced	transduce	VBN
390	395	HIV-1	HIV-1	NNP
396	400	long	long	JJ
401	409	terminal	terminal	JJ
410	416	repeat	repeat	NN
417	418	(	(	(
418	428	LTR)-IFNA2	LTR)-IFNA2	NNP
429	430	(	(	(
430	433	the	the	DT
434	437	new	new	JJ
438	446	approved	approve	VBN
447	459	nomenclature	nomenclature	NN
460	463	for	for	IN
464	467	IFN	IFN	NNP
468	473	genes	gene	NNS
474	476	is	be	VBZ
477	481	used	use	VBN
482	492	throughout	throughout	IN
493	497	this	this	DT
498	505	article	article	NN
505	506	)	)	)
507	513	hybrid	hybrid	NN
514	518	gene	gene	NN
519	521	to	to	TO
522	525	the	the	DT
526	540	HIV-1-infected	hiv-1-infected	JJ
541	546	cells	cell	NNS
546	547	,	,	,
548	553	HIV-1	HIV-1	NNP
554	557	LTR	LTR	NNP
558	561	was	be	VBD
562	570	modified	modify	VBN
570	571	.	.	.

572	580	Deletion	deletion	NN
581	583	of	of	IN
584	587	the	the	DT
588	596	NF-kappa	NF-kappa	NNP
597	598	B	B	NNP
599	607	elements	element	NNS
608	610	of	of	IN
611	614	the	the	DT
615	620	HIV-1	HIV-1	NNP
621	624	LTR	LTR	NNP
625	638	significantly	significantly	RB
639	648	inhibited	inhibit	VBD
649	661	Tat-mediated	tat-mediated	JJ
662	677	transactivation	transactivation	NN
678	680	in	in	IN
681	687	T-cell	t-cell	NN
688	693	lines	line	NNS
693	694	,	,	,
695	697	as	as	RB
698	702	well	well	RB
703	705	as	as	IN
706	708	in	in	IN
709	710	a	a	DT
711	719	monocyte	monocyte	NN
720	724	line	line	NN
724	725	,	,	,
726	730	U937	U937	NNP
730	731	.	.	.

732	743	Replacement	replacement	NN
744	746	of	of	IN
747	750	the	the	DT
751	759	NF-kappa	NF-kappa	NNP
760	761	B	B	NNP
762	770	elements	element	NNS
771	773	in	in	IN
774	777	the	the	DT
778	783	HIV-1	HIV-1	NNP
784	787	LTR	LTR	NNP
788	790	by	by	IN
791	792	a	a	DT
793	796	DNA	DNA	NNP
797	805	fragment	fragment	NN
806	813	derived	derive	VBN
814	818	from	from	IN
819	822	the	the	DT
823	834	5’-flanking	5'-flanking	JJ
835	841	region	region	NN
842	844	of	of	IN
845	859	IFN-stimulated	ifn-stimulated	JJ
860	864	gene	gene	NN
865	867	15	15	CD
868	869	(	(	(
869	874	ISG15	ISG15	NNP
874	875	)	)	)
875	876	,	,	,
877	887	containing	contain	VBG
888	891	the	the	DT
892	906	IFN-stimulated	ifn-stimulated	JJ
907	915	response	response	NN
916	923	element	element	NN
923	924	,	,	,
925	934	partially	partially	RB
935	943	restored	restore	VBD
944	956	Tat-mediated	tat-mediated	JJ
957	967	activation	activation	NN
968	970	of	of	IN
971	974	LTR	LTR	NNP
975	977	in	in	IN
978	979	T	t	NN
980	985	cells	cell	NNS
986	988	as	as	RB
989	993	well	well	RB
994	996	as	as	IN
997	999	in	in	IN
1000	1009	monocytes	monocyte	NNS
1009	1010	.	.	.

1011	1020	Insertion	Insertion	NNP
1021	1023	of	of	IN
1024	1028	this	this	DT
1029	1037	chimeric	chimeric	JJ
1038	1046	promoter	promoter	NN
1047	1048	(	(	(
1048	1053	ISG15	ISG15	NNP
1054	1057	LTR	LTR	NNP
1057	1058	)	)	)
1059	1067	upstream	upstream	RB
1068	1070	of	of	IN
1071	1074	the	the	DT
1075	1080	human	human	JJ
1081	1086	IFNA2	ifna2	NN
1087	1091	gene	gene	NN
1092	1100	directed	direct	VBD
1101	1105	high	high	JJ
1106	1112	levels	level	NNS
1113	1115	of	of	IN
1116	1119	IFN	ifn	NN
1120	1129	synthesis	synthesis	NN
1130	1132	in	in	IN
1133	1147	Tat-expressing	tat-expressing	JJ
1148	1153	cells	cell	NNS
1153	1154	,	,	,
1155	1160	while	while	IN
1161	1165	this	this	DT
1166	1174	promoter	promoter	NN
1175	1178	was	be	VBD
1179	1182	not	not	RB
1183	1193	responsive	responsive	JJ
1194	1196	to	to	TO
1197	1202	tumor	tumor	NN
1203	1211	necrosis	necrosis	NN
1212	1218	factor	factor	NN
1219	1233	alpha-mediated	alpha-mediated	JJ
1234	1244	activation	activation	NN
1244	1245	.	.	.

1246	1259	ISG15-LTR-IFN	isg15-ltr-ifn	NN
1260	1266	hybrid	hybrid	NN
1267	1271	gene	gene	NN
1272	1280	inserted	insert	VBN
1281	1285	into	into	IN
1286	1289	the	the	DT
1290	1300	retrovirus	retrovirus	NN
1301	1307	vector	vector	NN
1308	1311	was	be	VBD
1312	1322	transduced	transduce	VBN
1323	1327	into	into	IN
1328	1334	Jurkat	Jurkat	NNP
1335	1338	and	and	CC
1339	1343	U937	u937	NN
1344	1349	cells	cell	NNS
1349	1350	.	.	.

1351	1359	Selected	select	VBN
1360	1371	transfected	transfecte	VBN
1372	1378	clones	clone	NNS
1379	1387	produced	produce	VBD
1388	1391	low	low	JJ
1392	1398	levels	level	NNS
1399	1401	of	of	IN
1402	1405	IFN	IFN	NNP
1406	1407	A	A	NNP
1408	1409	(	(	(
1409	1413	IFNA	IFNA	NNP
1413	1414	)	)	)
1415	1429	constitutively	constitutively	RB
1429	1430	,	,	,
1431	1434	and	and	CC
1435	1440	their	their	PRP$
1441	1450	abilities	ability	NNS
1451	1453	to	to	TO
1454	1461	express	express	VB
1462	1475	interleukin-2	interleukin-2	NN
1476	1479	and	and	CC
1480	1493	interleukin-2	interleukin-2	NN
1494	1502	receptor	receptor	NN
1503	1507	upon	upon	IN
1508	1519	stimulation	stimulation	NN
1520	1524	with	with	IN
1525	1543	phytohemagglutinin	phytohemagglutinin	NN
1544	1547	and	and	CC
1548	1555	phorbol	phorbol	NN
1556	1565	myristate	myristate	NN
1566	1573	acetate	acetate	NN
1574	1578	were	be	VBD
1579	1587	retained	retain	VBN
1587	1588	.	.	.

1589	1600	Enhancement	enhancement	NN
1601	1603	of	of	IN
1604	1608	IFNA	IFNA	NNP
1609	1618	synthesis	synthesis	NN
1619	1627	observed	observe	VBN
1628	1632	upon	upon	IN
1633	1638	HIV-1	HIV-1	NNP
1639	1648	infection	infection	NN
1649	1657	resulted	result	VBD
1658	1660	in	in	IN
1661	1672	significant	significant	JJ
1673	1683	inhibition	inhibition	NN
1684	1686	of	of	IN
1687	1692	HIV-1	HIV-1	NNP
1693	1704	replication	replication	NN
1705	1708	for	for	IN
1709	1710	a	a	DT
1711	1717	period	period	NN
1718	1720	of	of	IN
1721	1723	at	at	IN
1724	1729	least	least	JJS
1730	1732	30	30	CD
1733	1737	days	day	NNS
1737	1738	.	.	.

1739	1744	Virus	virus	NN
1745	1753	isolated	isolate	VBN
1754	1758	from	from	IN
1759	1773	IFNA-producing	ifna-producing	JJ
1774	1779	cells	cell	NNS
1780	1783	was	be	VBD
1784	1788	able	able	JJ
1789	1791	to	to	TO
1792	1801	replicate	replicate	VB
1802	1804	in	in	IN
1805	1808	the	the	DT
1809	1813	U937	u937	NN
1814	1819	cells	cell	NNS
1820	1823	but	but	CC
1824	1827	did	do	VBD
1828	1831	not	not	RB
1832	1841	replicate	replicate	VB
1842	1853	efficiently	efficiently	RB
1854	1856	in	in	IN
1857	1861	U937	u937	NN
1862	1867	cells	cell	NNS
1868	1878	transduced	transduce	VBN
1879	1883	with	with	IN
1884	1887	the	the	DT
1888	1892	IFNA	IFNA	NNP
1893	1897	gene	gene	NN
1897	1898	.	.	.

1899	1904	These	these	DT
1905	1912	results	result	NNS
1913	1920	suggest	suggest	VBP
1921	1925	that	that	IN
1926	1935	targeting	target	VBG
1936	1939	IFN	ifn	NN
1940	1949	synthesis	synthesis	NN
1950	1952	to	to	TO
1953	1967	HIV-1-infected	hiv-1-infected	JJ
1968	1973	cells	cell	NNS
1974	1976	is	be	VBZ
1977	1979	an	an	DT
1980	1990	attainable	attainable	JJ
1991	1995	goal	goal	NN
1996	1999	and	and	CC
2000	2004	that	that	IN
2005	2014	autocrine	autocrine	JJ
2015	2018	IFN	IFN	NNP
2019	2028	synthesis	synthesis	NN
2029	2036	results	result	VBZ
2037	2039	in	in	IN
2040	2041	a	a	DT
2042	2054	long-lasting	long-lasting	JJ
2055	2058	and	and	CC
2059	2068	permanent	permanent	JJ
2069	2080	suppression	suppression	NN
2081	2083	of	of	IN
2084	2089	HIV-1	HIV-1	NNP
2090	2101	replication	replication	NN
2101	2102	.	.	.